or Try an Advanced Search...

    Technical Analysis for ERAS - Erasca, Inc

    Grade Last Price % Change Price Change
    C 2.64 -5.38% -0.15
    ERAS closed down 5.38 percent on Wednesday, November 20, 2024, on 38 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical ERAS trend table...
    Date Alert Name Type % Chg
    Fell Below 50 DMA Bearish 0.00%
    180 Bearish Setup Bearish Swing Setup 0.00%
    Stochastic Reached Oversold Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    20 DMA Resistance Bearish -5.38%
    Crossed Above 50 DMA Bullish -5.38%
    Inside Day Range Contraction -5.38%
    20 DMA Resistance Bearish -3.30%
    50 DMA Resistance Bearish -3.30%
    Gapped Up Strength -3.30%
    Older End-of-Day Signals for ERAS ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 17 hours ago
    Fell Below Previous Day's Low about 18 hours ago
    Possible NR7 about 18 hours ago
    Possible Inside Day about 18 hours ago
    60 Minute Opening Range Breakdown about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ERAS Chart by TradingView
    Basic chart:

    Profile

    Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Acute Myeloid Leukemia Colorectal Cancer Enzymes Tyrosine Kinase Receptors Oncogenes NSCLC Non Small Cell Lung Carcinoma Metastatic Solid Tumors Ras Gtpase Bemcentinib Ptpn11

    Is ERAS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
    Nov 13 Erasca reports Q3 results
    Nov 12 Erasca Reports Third Quarter 2024 Business Updates and Financial Results
    Nov 5 Erasca to Present at Upcoming Investor Conferences
    Oct 30 Erasca Insiders Added US$1.95m Of Stock To Their Holdings
    Oct 24 Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
    Sep 30 Erasca: New Focus After Restructuring, But Need More Differentiation
    Sep 25 Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
    Sep 23 Erasca, Inc. (NASDAQ:ERAS) is favoured by institutional owners who hold 61% of the company
    Aug 29 Erasca to Present at Upcoming Investor Conferences in September
    See more ERAS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.45
    52 Week Low 1.51
    Average Volume 1,922,373
    200-Day Moving Average 2.47
    50-Day Moving Average 2.76
    20-Day Moving Average 2.83
    10-Day Moving Average 2.88
    Average True Range 0.20
    RSI (14) 43.18
    ADX 14.79
    +DI 19.10
    -DI 20.38
    Chandelier Exit (Long, 3 ATRs) 2.69
    Chandelier Exit (Short, 3 ATRs) 3.05
    Upper Bollinger Bands 3.20
    Lower Bollinger Band 2.45
    Percent B (%b) 0.25
    BandWidth 26.69
    MACD Line 0.00
    MACD Signal Line 0.04
    MACD Histogram -0.0347
    Fundamentals Value
    Market Cap 398.87 Million
    Num Shares 151 Million
    EPS -1.73
    Price-to-Earnings (P/E) Ratio -1.53
    Price-to-Sales 0.00
    Price-to-Book 0.78
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.97
    Resistance 3 (R3) 2.99 2.91 2.92
    Resistance 2 (R2) 2.91 2.82 2.90 2.90
    Resistance 1 (R1) 2.77 2.77 2.73 2.75 2.88
    Pivot Point 2.69 2.69 2.67 2.68 2.69
    Support 1 (S1) 2.55 2.60 2.51 2.53 2.40
    Support 2 (S2) 2.47 2.55 2.46 2.38
    Support 3 (S3) 2.33 2.47 2.37
    Support 4 (S4) 2.31